Serepta, Prosensa to Present on DMD Research at Conference on RNA Therapies

Serepta, Prosensa to Present on DMD Research at Conference on RNA Therapies
0
(0)

shutterstock_134734202Biopharmaceutical company Prosensa announced that they will present at the 6th annual conference on RNA Therapeutics, which will take place between February 16 and 17, 2015 in London, and will discuss the latest developments of its investigational drug for the treatment of Duchenne muscular dystrophy. Prosensa, which earlier last week was acquired by U.S. drug manufacturer BioMarin, will be joining another promising DMD drug developer, Serepta Therapeutics, at the conference.

Prosensa is currently working on therapies for DMD, and their company’s research has been particularly important in advancing RNA-based medications that are able to target an abnormality in part of the dystrophin gene. Similarly, both Prosensa’s and Sarepta Therapeutics’ research is focused on targeting abnormalities in exon 51, and if they succeed in their research and development, it may impact the lives of about 13 percent of the patients suffering from Duchenne — a subject that both companies will address at the conference.

The presentation, entitled Exon Skipping in Duchenne Muscular Dystrophy, will be hosted by Prosensa’s Chief Medical Officer and SVP of R&D, Giles Campion, who will be discussing the company’s clinical programs and providing guidance on accelerating regulatory paths to approval. Campion will also be leading a round table discussion on the development of RNA-based therapies for the treatment of rare diseases.

[adrotate group=”3″]

Sarepta will present a panel entitled From RNA splicing to Eterplirsen trials — a drug for Duchenne muscular dystrophy, which will be hosted by prominent scientist Ryszard Kole. The investigator will be presenting the company’s findings from a recent trial, as well as addressing questions such as the invention of RNA splicing and the assessment of Eterplirsen induced exon skipping of 51 in dystrophin pre-mRNA in DMD patients.

BioMarin acquired Prosensa in a $680 million deal, which includes two additional payments of approximately $80 million, pending regulatory approvals of the medication being currently developed by Prosensa for the treatment of Duchenne. Prosensa is currently one of the few biopharmaceutical companies in the world dedicated to creating therapies targeting the progressive muscle-wasting disorder.

In addition, the company remains dedicated to raising awareness about the disease, and has partnered with the national nonprofit organization CureDuchenne to present their collaborative project at the 6th annual Partnering for Cures event. Together with 1,000 medical research leaders, investors, and decision-makers, the event was organized to enhance partnerships to accelerate and improve outcomes from research on the disease.

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • Hockey player Ryan Getzlaf
  • Sarepta partnership
  • MYO-101 for LGMD2E
  • ICER review

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?